%	O
%	O
TITLE	O

Differences	O
in	O
the	O
Prevalence	B-Incidence_or_Prevalence
of	O
Human	O
Papillomavirus	O
(	O
HPV	O
)	O
in	O
Head	O
and	O
Neck	O
Squamous	O
Cell	O
Cancers	O
by	O
Sex	O
,	O
Race	O
,	O
Anatomic	O
Tumor	O
Site	O
,	O
and	O
HPV	O
Detection	O
Method	O
.	O

%	O
%	O
ABSTRACT	O

Human	O
papillomavirus	O
(	O
HPV	O
)	O
causes	O
an	O
increasing	O
proportion	O
of	O
oropharyngeal	O
squamous	O
cell	O
carcinomas	O
(	O
OPSCCs	O
)	O
,	O
particularly	O
in	O
white	O
men	O
.	O

The	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
among	O
other	O
demographic	O
groups	O
and	O
other	O
anatomic	O
sites	O
of	O
HNSCC	O
is	O
unclear	O
.	O
To	O
explore	O
the	O
role	O
of	O
HPV	O
tumor	O
status	O
among	O
women	O
and	O
nonwhites	O
with	O
OPSCC	O
and	O
patients	O
with	O
nonoropharyngeal	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
non	O
-	O
OP	O
HNSCC	O
)	O
.	O
Retrospective	B-Study_Type
cohort	I-Study_Type
study	I-Study_Type
at	O
2	O
tertiary	O
academic	O
centers	O
including	O
cases	O
diagnosed	O
1995	B-Study_Time
through	I-Study_Time
2012	I-Study_Time
,	O
oversampled	O
for	O
minorities	O
and	O
females	O
.	O

A	O
stratified	O
random	O
sample	O
of	O
863	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
newly	I-Study_Cohort
diagnosed	I-Study_Cohort
SCC	I-Study_Cohort
of	I-Study_Cohort
the	I-Study_Cohort
oral	I-Study_Cohort
cavity	I-Study_Cohort
,	I-Study_Cohort
oropharynx	I-Study_Cohort
,	I-Study_Cohort
larynx	I-Study_Cohort
,	I-Study_Cohort
or	I-Study_Cohort
nasopharynx	I-Study_Cohort
was	O
used	O
.	O
Outcomes	O
were	O
HPV	O
status	O
as	O
measured	O
by	O
p16	B-HPV_Lab_Technique
immunohistochemical	I-HPV_Lab_Technique
analysis	I-HPV_Lab_Technique
,	O
HPV16	B-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
,	O
and	O
high	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
risk	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
E6	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
E7	I-HPV_Lab_Technique
mRNA	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
.	O
Of	O
863	B-Study_Cohort
patients	I-Study_Cohort
,	O
551	O
(	O
63	O
.	O
9	O
%	O
)	O
were	O
male	O
and	O
median	O
age	O
was	O
58	O
years	O
(	O
interquartile	O
range	O
,	O
51	B-Minimum_Age_in_Study_Cohort
-	O
68	B-Maximum_Age_in_Study_Cohort
years	O
)	O
.	O

Among	O
240	O
OPSCCs	O
,	O
144	O
(	O
60	O
%	O
)	O
were	O
p16	O
positive	O
(	O
p16	O
+	O
)	O
,	O
115	O
(	O
48	O
%	O
)	O
were	O
HPV16	O
DNA	O
ISH	B-HPV_Lab_Technique
positive	O
(	O
ISH16	O
+	O
)	O
,	O
and	O
134	O
(	O
56	O
%	O
)	O
were	O
positive	O
for	O
any	O
oncogenic	O
HPV	O
type	O
(	O
ISH	B-HPV_Lab_Technique
+	O
)	O
.	O

From	O
1995	B-Study_Time
to	I-Study_Time
2012	I-Study_Time
,	O
the	O
proportion	O
of	O
p16	O
+	O
OPSCC	O
increased	O
significantly	O
among	O
women	O
(	O
from	O
29	O
%	O
to	O
77	O
%	O
;	O
Pâ€‰=â€‰	O
.	O
005	O
for	O
trend	O
)	O
and	O
men	O
(	O
36	O
%	O
to	O
72	O
%	O
;	O
Pâ€‰	O
<	O
â€‰	O
.	O
001	O
for	O
trend	O
)	O
,	O
as	O
well	O
as	O
among	O
whites	O
(	O
39	O
%	O
to	O
86	O
%	O
;	O
Pâ€‰	O
<	O
â€‰	O
.	O
001	O
for	O
trend	O
)	O
and	O
nonwhites	O
(	O
32	O
%	O
to	O
62	O
%	O
;	O
Pâ€‰=â€‰	O
.	O
02	O
for	O
trend	O
)	O
.	O

Similar	O
results	O
were	O
observed	O
for	O
ISH	O
+	O
OPSCC	O
(	O
Pâ€‰â‰¤â€‰	O
.	O
01	O
for	O
all	O
)	O
.	O

Among	O
623	O
non	O
-	O
OP	O
HNSCCs	O
,	O
a	O
higher	O
proportion	O
were	O
p16	O
+	O
compared	O
with	O
ISH	O
positive	O
(	O
62	O
[	O
10	O
%	O
]	O
vs	O
30	O
[	O
5	O
%	O
]	O
;	O
Pâ€‰=â€‰	O
.	O
001	O
)	O
.	O

A	O
high	O
proportion	O
(	O
26	O
of	O
62	O
[	O
42	O
%	O
]	O
)	O
of	O
these	O
p16	O
+	O
non	O
-	O
OP	O
HNSCCs	O
were	O
found	O
in	O
sites	O
adjacent	O
to	O
the	O
oropharynx	O
.	O

The	O
proportion	O
of	O
p16	O
+	O
and	O
ISH	O
+	O
non	O
-	O
OP	O
HNSCCs	O
were	O
similar	O
by	O
sex	O
.	O

Over	O
time	O
,	O
the	O
proportion	O
of	O
non	O
-	O
OP	O
HNSCCs	O
that	O
were	O
p16	O
+	O
(	O
or	O
ISH	O
+	O
)	O
increased	O
among	O
whites	O
(	O
Pâ€‰=â€‰	O
.	O
04	O
for	O
trend	O
)	O
but	O
not	O
among	O
nonwhites	O
(	O
each	O
Pâ€‰	O
>	O
.	O
51	O
for	O
trend	O
)	O
.	O

Among	O
OPSCCs	O
,	O
p16	O
had	O
high	O
sensitivity	O
(	O
100	O
%	O
)	O
,	O
specificity	O
(	O
91	O
%	O
)	O
,	O
and	O
positive	O
(	O
93	O
%	O
)	O
and	O
negative	O
predictive	O
value	O
(	O
100	O
%	O
)	O
for	O
ISH	B-HPV_Lab_Technique
positivity	O
.	O

In	O
non	O
-	O
OP	O
HNSCCs	O
,	O
p16	O
had	O
lower	O
sensitivity	O
(	O
83	O
%	O
)	O
and	O
positive	O
predictive	O
value	O
(	O
40	O
%	O
)	O
but	O
high	O
specificity	O
(	O
94	O
%	O
)	O
and	O
negative	O
predictive	O
value	O
(	O
99	O
%	O
)	O
for	O
ISH	B-HPV_Lab_Technique
positivity	O
.	O
During	O
1995	O
through	O
2012	O
,	O
the	O
proportion	O
of	O
OPSCCs	O
caused	O
by	O
HPV	O
has	O
increased	O
significantly	O
.	O

This	O
increase	O
was	O
not	O
restricted	O
to	O
white	O
men	O
but	O
was	O
a	O
consistent	O
trend	O
for	O
women	O
and	O
men	O
,	O
as	O
well	O
as	O
for	O
white	O
and	O
nonwhite	O
racial	O
groups	O
.	O

Few	O
non	O
-	O
OP	O
HNSCCs	O
were	O
HPV	O
related	O
.	O

P16	O
positivity	O
was	O
a	O
good	O
surrogate	O
for	O
ISH	B-HPV_Lab_Technique
+	O
tumor	O
status	O
among	O
OPSCC	O
,	O
but	O
not	O
a	O
good	O
surrogate	O
for	O
non	O
-	O
OP	O
HNSCC	O
.	O

%	O
%	O
METHODS	O

This	O
was	O
a	O
retrospective	B-Study_Type
study	I-Study_Type
of	O
incident	B-Incidence_or_Prevalence
HNSCC	O
cases	O
diagnosed	O
between	O
1995	B-Study_Time
and	I-Study_Time
2012	I-Study_Time
at	O
2	O
comprehensive	O
can	O
-	O
cer	O
centers	O
,	O
the	O
Johns	O
Hopkins	O
Hospital	O
Sydney	O
Kimmel	O
Comprehensive	O
Cancer	O
Center	O
(	O
JHH	O
)	O
(	O
Baltimore	B-Study_Location
,	I-Study_Location
Maryland	I-Study_Location
)	O
and	O
the	O
University	O
of	O
California–San	B-Study_Location
Francisco	I-Study_Location
Helen	O
Diller	O
Family	O
Comprehensive	O
Cancer	O
Center	O
and	O
affiliated	O
hospi	O
-	O
tals	O
(	O
UCSF	O
)	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
at	O
each	O
participating	O
institution	O
.	O

Informed	O
consent	O
was	O
waived	O
by	O
the	O
institutional	O
review	O
board	O
due	O
to	O
the	O
retrospective	O
nature	O
of	O
the	O
study	O
.	O

A	O
database	O
of	O
all	O
diag	O
-	O
nosed	O
SCC	O
cases	O
of	O
the	O
OP	O
,	O
oral	O
cavity	O
,	O
nasopharynx	O
,	O
and	O
larynx	O
was	O
created	O
using	O
institutional	O
cancer	O
registries	O
,	O
stratified	O
by	O
sex	O
and	O
race	O
.	O

Cases	O
from	O
each	O
tumor	O
site	O
were	O
randomly	O
sampled	O
(	O
when	O
possible	O
)	O
in	O
sex	O
and	O
race	O
groups	O
of	O
interest	O
to	O
oversample	O
cases	O
occurring	O
in	O
minorities	O
and	O
women	O
.	O

Cases	O
in	O
Asian	O
and	O
Hispanic	O
patients	O
could	O
not	O
be	O
randomly	O
sampled	O
due	O
to	O
the	O
lower	O
overall	O
numbers	O
and	O
were	O
therefore	O
all	O
selected	O
for	O
inclusion	O
.	O

All	O
medical	O
records	O
were	O
reviewed	O
to	O
ascertain	O
patient	O
demographic	O
characteristics	O
(	O
sex	O
,	O
race	O
,	O
age	O
)	O
,	O
tumor	O
site	O
,	O
tu	O
-	O
mor	O
characteristics	O
including	O
specifically	O
whether	O
OP	O
adja	O
-	O
cent	O
or	O
nonadjacent	O
,	O
and	O
lifetime	O
and	O
current	O
tobacco	O
and	O
al	O
-	O
cohol	O
use	O
at	O
diagnosis	O
.	O

Race	O
was	O
categorized	O
based	O
on	O
race	O
and	O
ethnicity	O
reported	O
in	O
the	O
institutional	O
cancer	O
registry	O
and	O
/	O
or	O
medical	O
record	O
.	O

Oropharynx	O
adjacent	O
was	O
defined	O
as	O
HNSCC	O
subsites	O
within	O
proximity	O
to	O
the	O
OP	O
including	O
posterior	O
tongue	O
,	O
posterolateral	O
tongue	O
,	O
retromolar	O
trigone	O
,	O
epiglottis	O
,	O
and	O
over	O
-	O
lapping	O
lesions	O
including	O
OP	O
.	O

Lifetime	O
use	O
was	O
defined	O
as	O
ever	O
regular	O
(	O
at	O
least	O
weekly	O
)	O
use	O
of	O
any	O
tobacco	O
or	O
alcohol	O
prod	O
-	O
uct	O
.	O

Current	O
use	O
was	O
defined	O
as	O
use	O
within	O
the	O
month	O
before	O
diagnosis	O
,	O
as	O
recorded	O
in	O
the	O
medical	O
record	O
.	O

There	O
were	O
1345	O
patients	O
originally	O
sampled	O
including	O
481	O
women	O
and	O
864	O
men	O
.	O

This	O
included	O
176	O
OP	O
,	O
174	O
oral	O
cav	O
-	O
ity	O
,	O
70	O
nasopharynx	O
,	O
and	O
199	O
larynx	O
cancers	O
at	O
JHH	O
and	O
163	O
OP	O
,	O
198	O
oral	O
cavity	O
,	O
198	O
nasopharynx	O
,	O
and	O
167	O
larynx	O
cancers	O
at	O
UCSF	O
.	O

Among	O
these	O
cases	O
,	O
863	O
(	O
64	O
%	O
)	O
had	O
a	O
pathologic	O
sample	B-HPV_Sample_Type
available	O
for	O
testing	O
and	O
were	O
therefore	O
considered	O
eligible	O
for	O
study	O
.	O

The	O
proportion	O
of	O
eligible	O
samples	B-HPV_Sample_Type
tested	O
was	O
similar	O
for	O
men	O
(	O
64	O
%	O
)	O
and	O
women	O
(	O
66	O
%	O
)	O
and	O
for	O
Asian	O
(	O
54	O
%	O
)	O
,	O
Hispanic	O
(	O
68	O
%	O
)	O
,	O
black	O
(	O
69	O
%	O
)	O
,	O
and	O
white	O
(	O
67	O
%	O
)	O
patients	O
.	O

All	O
eligible	O
samples	B-HPV_Sample_Type
were	O
tested	O
for	O
HPV	O
-	O
related	O
markers	O
,	O
as	O
described	O
in	O
the	O
next	O
subsection	O
.	O

Testing	O
Methods	O

Hematoxylin	O
-	O
eosin	O
slides	O
were	O
reviewed	O
by	O
a	O
head	O
and	O
neck	O
pathologist	O
(	O
W	O
.	O
H	O
.	O
W	O
.	O
)	O
at	O
JHH	O
and	O
UCSF	O
.	O

Histologic	O
subtype	O
was	O
confirmed	O
,	O
and	O
relevant	O
paraffin	O
-	O
embedded	O
slides	O
or	O
paraf	O
-	O
fin	O
blocks	O
were	O
used	O
for	O
HPV	O
detection	O
.	O

All	O
HPV	O
detection	O
was	O
performed	O
centrally	O
by	O
the	O
JHH	O
pathology	O
laboratory	O
and	O
in	O
-	O
terpreted	O
by	O
a	O
single	O
head	O
and	O
neck	O
pathologist	O
(	O
W	O
.	O
H	O
.	O
W	O
.	O
)	O
.	O

Human	O
papillomavirus	O
status	O
was	O
determined	O
using	O
an	O
algo	O
-	O
rithm	O
that	O
incorporates	O
both	O
p16	B-HPV_Lab_Technique
immunohistochemical	I-HPV_Lab_Technique
analy	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
sis	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
MTM	I-HPV_Lab_Technique
Laboratories	I-HPV_Lab_Technique
)	O
,	O
HPV16	B-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Dako	I-HPV_Lab_Technique
GenPoint	I-HPV_Lab_Technique
)	O
,	O
and	O
high	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
risk	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
E6	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
E7	I-HPV_Lab_Technique
mRNA	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
called	I-HPV_Lab_Technique
RNA	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
RNAscope	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Advanced	I-HPV_Lab_Technique
Cell	I-HPV_Lab_Technique
Diagnostics	I-HPV_Lab_Technique
)	O
.	O

P16	O
expres	O
-	O
sion	O
was	O
scored	O
as	O
positive	O
if	O
strong	O
and	O
diffuse	O
nuclear	O
and	O
cytoplasmic	O
staining	O
was	O
present	O
in	O
at	O
least	O
70	O
%	O
of	O
the	O
tumor	O
.	O

For	O
HPV16	B-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
(	O
hereafter	O
ISH16	O
)	O
,	O
punctate	O
hybrid	O
-	O
ization	O
signals	O
localized	O
to	O
the	O
tumor	O
cell	O
nuclei	O
defined	O
a	O

HPV16	O
-	O
positive	O
tumor	O
.	O

Among	O
73	O
tumors	O
that	O
were	O
p16	O
posi	O
-	O
tive	O
but	O
ISH16	O
negative	O
,	O
additional	O
testing	O
was	O
performed	O
using	O
an	O
RNA	O
ISH	O
probe	O
targeting	O
18	O
high	O
-	O
risk	O
HPV	O
genotypes	O
(	O
16	O
,	O
18	O
,	O
26	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
53	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
66	O
,	O
68	O
,	O
73	O
,	O
and	O

82	O
)	O
.	O
14	O
Only	O
26	O
(	O
36	O
%	O
)	O
of	O
these	O
cases	O
were	O
RNA	O
ISH	B-HPV_Lab_Technique
positive	O
;	O
these	O
26	O
RNA	O
ISH–positive	O
cases	O
were	O
combined	O
with	O
DNA	O
ISH16–	O
positive	O
cases	O
into	O
an	O
“ISH	O
-	O
positive”	O
category	O
.	O

Statistical	O
Analysis	O

Characteristics	O
of	O
patients	O
at	O
each	O
study	O
site	O
were	O
summa	O
-	O
rized	O
with	O
descriptive	O
statistics	O
.	O

Race	O
,	O
sex	O
,	O
and	O
age	O
were	O
ob	O
-	O
tained	O
from	O
institutional	O
cancer	O
registries	O
and	O
confirmed	O
using	O
medical	O
record	O
abstraction	O
for	O
each	O
case	O
.	O

Race	O
and	O
ethnicity	O
were	O
categorized	O
as	O
white	O
non	O
-	O
Hispanic	O
,	O
black	O
non	O
-	O
Hispanic	O
,	O
Asian	O
non	O
-	O
Hispanic	O
,	O
and	O
Hispanic	O
any	O
race	O
,	O
and	O
referred	O
to	O
as	O
white	O
,	O
black	O
,	O
Asian	O
,	O
and	O
Hispanic	O
hereafter	O
.	O

Patients	O
of	O
other	O
races	O
were	O
not	O
sampled	O
due	O
to	O
insufficient	O
numbers	O
.	O

The	O
prevalence	B-Incidence_or_Prevalence
of	O
p16	O
positivity	O
,	O
ISH16	O
positivity	O
,	O
and	O
ISH	O
positivity	O
were	O
described	O
by	O
tumor	O
site	O
,	O
sex	O
,	O
and	O
race	O
.	O

Differ	O
-	O
ences	O
in	O
prevalence	B-Incidence_or_Prevalence
were	O
calculated	O
using	O
the	O
χ2	O
test	O
.	O

Perfor	O
-	O
mance	O
characteristics	O
(	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predic	O
-	O
tive	O
value	O
,	O
and	O
negative	O
predictive	O
value	O
)	O
of	O
p16	O
status	O
were	O
compared	O
with	O
ISH	O
status	O
.	O

The	O
benchmark	O
for	O
a	O
tumor	O
to	O
be	O
consider	O
HPV	O
related	O
was	O
ISH	O
positivity	O
,	O
which	O
included	O
being	O
HPV16	O
positive	O
by	O
DNA	O
ISH	O
testing	O
or	O
high	O
-	O
risk	O
HPV	O
positive	O
by	O
RNA	O
ISH	O
testing	O
.	O

For	O
some	O
analyses	O
,	O
oral	O
cavity	O
,	O
laryngeal	O
,	O
and	O
nasopharyngeal	O
tumors	O
were	O
combined	O
and	O
referred	O
to	O
as	O
non	O
-	O
OP	O
HNSCC	O
.	O

The	O
prevalence	B-Incidence_or_Prevalence
of	O
p16	O
-	O
positive	O
and	O
ISH	O
-	O
positive	O
HNSCC	O
was	O
explored	O
over	O
calendar	O
time	O
,	O
by	O
sex	O
and	O
race	O
,	O
and	O
stratified	O
by	O
OPSCC	O
or	O
non	O
-	O
OP	O
HNSCC	O
.	O

